Evolus, Inc.EOLSEarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
Evolus, Inc. is a medical aesthetics company focused on developing and commercializing non-surgical cosmetic treatment solutions. Its flagship product is a prescription neuromodulator designed to reduce moderate to severe glabellar frown lines, serving licensed aesthetic healthcare providers and consumers across North America, Europe, and key Asia-Pacific regional markets.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| Perceptive Advisors LLC | 8.50% | 5.4M | ▲ +1.60pp | 2024-11-14 |
| NOS. of Above Persons | 7.70% | 4.8M | ▲ +2.30pp | 2024-11-14 |
| BlackRock, Inc. | 5.80% | 3.3M | — | 2024-01-29 |
| The Vanguard Group | 5.15% | 2.9M | — | 2024-02-13 |
| Nantahala | 5.10% | 2.9M | — | 2024-02-14 |
| Millennium Management LLC | 4.60% | 2.6M | — | 2023-05-09 |
| Stonepine Capital Management, LLC | 2.20% | 1.4M | ▼ -7.10pp | 2024-11-13 |
| First Manhattan Co. LLC | 0.86% | 490.0K | — | 2024-02-12 |
| Alphaeon 1 LLC | 0.00% | 30.1K | — | 2023-08-14 |
| OF ABOVE PERSONS | 0.00% | 1.8K | — | 2023-10-04 |
Insider Transactions
Net 90d: −$796.9K · buys $0 / sells $796.9KRange:
Action:
Role:
| Insider | Role | Action | ||||
|---|---|---|---|---|---|---|
| 2026-03-20 | MOATAZEDI DAVID | See Remarks | Sell (open market) | 13.7K | $4.75 | $64.9K |
| 2026-03-20 | Rui Avelar | See Remarks | Sell (open market) | 3.1K | $4.75 | $14.8K |
| 2026-03-17 | Rui Avelar | See Remarks | Sell (open market) | 30.0K | $4.89 | $146.6K |
| 2026-03-17 | MOATAZEDI DAVID | See Remarks | Sell (open market) | 116.7K | $4.89 | $570.6K |
| 2026-03-16 | Rui Avelar | See Remarks | Option exercise | 8.8K | $0.00 | $0 |
| 2026-03-16 | MOATAZEDI DAVID | See Remarks | Option exercise | 67.5K | $0.00 | $0 |
| 2026-02-17 | Parschauer Karah Herdman | Director | Grant | 45.6K | $0.00 | $0 |
| 2026-02-17 | Brady Stewart | Director | Grant | 45.6K | $0.00 | $0 |
| 2026-02-17 | MOATAZEDI DAVID | See Remarks | Grant | 313.2K | $0.00 | $0 |
| 2026-02-17 | Tatjana Mitchell | Chief Financial Officer | Grant | 121.5K | $0.00 | $0 |
1–10 of 14
Page 1 / 2